Phase III trials have shown activity of T‐DM1 in HER2+ metastatic disease after previous lines of treatment including trastuzumab and lapatinib, with improvements in both PFS and OS.109, 110. The gene discussed is ERBB2; the disease is metastatic neoplasm.